Edoc Acquisition Corp. (NASDAQ:ADOC) announced this afternoon that it has mutually terminated its combination with biotechnology firm Calidi Biotherapeutics, Inc.
This morning, Edoc filed an 8-K notifying shareholders that it had postponed its scheduled extension vote from 10AM to 8PM this evening. However, the deal was subsequently terminated ahead of that meeting with Edoc also stating they intend to keep searching for a new business combination target.
Nonetheless, Edoc and Calidi are keeping the door slightly open stating that they both “may continue to discuss the possibility of engaging in a business combination, but there can be no assurance that those discussions will result in a transaction.”
Edoc will still hold its extension vote this evening to move its completion deadline to February 12, 2023. That would give Edoc an additional 6 months to search and announce a new combination agreement. However, its original trust value of $91.5 million had previously been whittled down to approximately $27.5 million at its last extension vote held on February 9.
Edoc announced its business combination agreement with Calidi on February 2, 2022, at an enterprise value of $449 million. La Jolla, California-based Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that delivers oncolytic viruses for targeted therapy against difficult-to-treat cancers.
Columbus Acquisition Corp (NASDAQ:COLAU) has filed for a $57.5 million IPO to give its team a second vehicle in circulation to hunt for deals. The same team IPO’d Eureka (NASDAQ:EURK) in July at a slightly smaller $50 million scale and this new SPAC would improve upon some of that foray’s terms. Both SPACs managed to...
At the SPAC of Dawn One week before Thanksgiving, SPACs are not filling up their plate with just five votes scheduled, all of which are extensions. Five of these are set to take place today, and investors are also set to get an update on one of the most successful de-SPACs of recent years. Industrial...
Terms Tracker for the Week Ending November 15, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. The drought in De-SPAC deals continues without a single announced combination since October 23rd. That’s more than three weeks now with SPACs experiencing a dry...
Few corners of the market have seen a bigger boost from the result of the US elections than the crypto industry, and SPACs are always sure to be drawn to where the action is. But, in crypto’s case, this is a play that SPACs have been involved in before, so the question is more of...
At the SPAC of Dawn As more information continues to trickle out about what investors should expect from the Trump 2.0 tax changes, it has become increasingly clear that the $7,500 EV tax credit is on the outs. Such a change could shift the strategies for many EV de-SPACs and prospective SPAC targets in the...